tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Nuvation Bio announces taletrectinib as preferred agent in NCCN Guidelines

Nuvation Bio (NUVB) announced that taletrectinib has been added as a preferred agent in the latest National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Non-Small Cell Lung Cancers, updated on June 20. Specifically, the NCCN Guidelines now include taletrectinib as a preferred agent for both first-line and subsequent therapy for ROS1-positive NSCLC, including specific recommendations for those with brain metastases and resistance mutations.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1